Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Jonathan Mill, Merit Cudkowicz, Angela Genge, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 12, pp. 1099-1110
Open Access | Times Cited: 522

Showing 1-25 of 522 citing articles:

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation
Richard J. Mead, Ning Shan, H. Joseph Reiser, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 3, pp. 185-212
Open Access | Times Cited: 261
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
Catherine J. Mummery, Anne Börjesson‐Hanson, D. Blackburn, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1437-1447
Open Access | Times Cited: 156
Neurofilaments as biomarkers in neurological disorders — towards clinical application
Michael Khalil, Charlotte E. Teunissen, Sylvain Lehmann, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 5, pp. 269-287
Closed Access | Times Cited: 111
Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants
Annwyne Houldsworth
Brain Communications (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 106
Tofersen: First Approval
Hannah A. Blair
Drugs (2023) Vol. 83, Iss. 11, pp. 1039-1043
Closed Access | Times Cited: 89
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
Marlen C. Lauffer, Willeke M. C. van Roon‐Mom, Annemieke Aartsma‐Rus
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 82
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Adam L. Boxer, Reisa A. Sperling
Cell (2023) Vol. 186, Iss. 22, pp. 4757-4772
Open Access | Times Cited: 78
The era of cryptic exons: implications for ALS-FTD
Puja R. Mehta, Anna‐Leigh Brown, Michael E. Ward, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 60
Current State and Future Directions in the Therapy of ALS
Laura Tzeplaeff, Sibylle Wilfling, Maria Viktoria Requardt, et al.
Cells (2023) Vol. 12, Iss. 11, pp. 1523-1523
Open Access | Times Cited: 58
Neurofilament light chain response during therapy with antisense oligonucleotide Tofersen in SOD1 ‐related ALS – treatment experience in clinical practice
Thomas Meyer, Peggy Schumann, Patrick Weydt, et al.
Muscle & Nerve (2023) Vol. 67, Iss. 6, pp. 515-521
Open Access | Times Cited: 57
The state of cell and gene therapy in 2023
Daniel Chancellor, David Barrett, Ly Nguyen-Jatkoe, et al.
Molecular Therapy (2023) Vol. 31, Iss. 12, pp. 3376-3388
Closed Access | Times Cited: 53
Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access program
Maximilian Wiesenfarth, Johannes Dorst, Dávid Brenner, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102495-102495
Open Access | Times Cited: 44
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)
Philip Van Damme, Ammar Al‐Chalabi, Peter M. Andersen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 6
Open Access | Times Cited: 36
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Jillian Belgrad, Hassan H. Fakih, Anastasia Khvorova
Nucleic Acid Therapeutics (2024) Vol. 34, Iss. 2, pp. 52-72
Closed Access | Times Cited: 33
Fluid biomarkers for amyotrophic lateral sclerosis: a review
Katherine E. Irwin, Udit Sheth, Philip C. Wong, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 28
NLRP3 inflammasome signalling in Alzheimer's disease
Róisín M. McManus, Eicke Latz
Neuropharmacology (2024) Vol. 252, pp. 109941-109941
Open Access | Times Cited: 27
Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease
Jarod Rutledge, Benoit Lehallier, Pardis Zarifkar, et al.
Acta Neuropathologica (2024) Vol. 147, Iss. 1
Open Access | Times Cited: 25
The sense of antisense therapies in ALS
Sien Hilde Van Daele, Pegah Masrori, Philip Van Damme, et al.
Trends in Molecular Medicine (2024) Vol. 30, Iss. 3, pp. 252-262
Open Access | Times Cited: 24
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
Leonard H. van den Berg, Jeffrey D. Rothstein, Pamela J. Shaw, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 9, pp. 901-912
Closed Access | Times Cited: 24
TDP-43-stratified single-cell proteomics of postmortem human spinal motor neurons reveals protein dynamics in amyotrophic lateral sclerosis
Amanda J. Guise, Santosh A. Misal, Richard H. Carson, et al.
Cell Reports (2024) Vol. 43, Iss. 1, pp. 113636-113636
Open Access | Times Cited: 23
Creutzfeldt–Jakob disease and other prion diseases
Inga Zerr, Anna Ladogana, Simon Mead, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 22
Regulated cell death and its role in Alzheimer’s disease and amyotrophic lateral sclerosis
Dietmar Rudolf Thal, Klara Gawor, Sebastiaan Moonen
Acta Neuropathologica (2024) Vol. 147, Iss. 1
Closed Access | Times Cited: 22
Disentangling tau: One protein, many therapeutic approaches
Courtney Lane‐Donovan, Adam L. Boxer
Neurotherapeutics (2024) Vol. 21, Iss. 2, pp. e00321-e00321
Open Access | Times Cited: 18
TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro
Qing-Qing Duan, Han Wang, Wei‐Ming Su, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications
Thomas G. Moens, Sandrine Da Cruz, Manuela Neumann, et al.
The Lancet Neurology (2025) Vol. 24, Iss. 2, pp. 166-178
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top